Neuren Pharmaceuticals Ltd (NEU)
Australian Securities Exchange · Australia · prices in AUD · close of 22 Oct 2026
Key indicators
| Last close | AUD 19.81 |
|---|---|
| 52-week range | 11.00 – 23.76 |
| Return, 1 month / 3 months | −5.3% / +15.4% |
| Return, 1 year / 3 years | −6.7% / +76.6% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 47 |
| Volatility (1 year) | 56.7% |
| Worst drawdown (1 year) | -48.6% |
| Average daily value traded | 10.13M AUD |
| Dividend yield | 0.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Neuren Pharmaceuticals is an Australian biopharmaceutical company that develops and commercialises treatments for rare neurodevelopmental disorders. Its main product is trofinetide, an oral medicine for Rett syndrome, and it also works on therapies for other conditions such as Fragile X syndrome and Phelan-McDermid syndrome. The company is based in Melbourne and its customers are mainly patients, clinicians and healthcare systems in markets where its medicines are approved and sold.
The shares are listed on the Australian Securities Exchange in Australia under the code NEU, and the price on this page is in Australian dollars (AUD). Our dividend records, which start in 2019, show payments in one calendar year. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Neuren Pharmaceuticals Ltd (NEU) trades on the Australian Securities Exchange in Australia. It last closed at AUD 19.81 on 22 October 2026.
Its price-based Market X-Ray is 73 out of 100 (a strong price profile), ranking 282 of 1,816 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 6.7% and over the last three months it rose 15.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 92 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 24.1% | ||
| From 52-week high | -16.2% | ||
| Momentum | 82 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 15.4% | ||
| 6-month return | 64.4% | ||
| 12-month return, skipping the last month | -1.5% | ||
| Stability (higher is calmer) | 63 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 56.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -48.6% | ||
| Liquidity | 92 · Strong | Trades actively. | |
| Average daily value traded | 10.13M AUD | ||
| Zero-volume days | 0.0% | ||
| Income | 3 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.8% | ||
| Years with dividends | 1 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +3.2% |
|---|---|
| 1 month | −5.3% |
| 3 months | +15.4% |
| 6 months | +64.4% |
| 1 year | −6.7% |
| 3 years | +76.6% |
| 5 years | +955.8% |
Signals
| 50-day / 200-day average | 20.58 / 15.96 |
|---|---|
| Golden / death cross (60 days) | Golden, 54 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.70 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 15 Sep 2026 | AUD 0.1500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.